This meta‐analysis found that once‐weekly BIF provides glycaemic control comparable to daily insulin degludec but with increased mild hypoglycaemia (54–69 mg/dL) and higher event rates of clinically significant/severe hypoglycaemia—particularly in type 1 diabetes and insulin‐experienced patients. This evidence concerns the gene INS and type 1 diabetes mellitus.